Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Start Date01 Sep 2024

Sponsor / Collaborator

Mayo Clinic

IRCT20231018059761N1 / RecruitingNot ApplicableIIT

Comparing the effectiveness of Citra-Lock 4% with heparin in controlling catheter dysfunction and infection in hemodialysis patients

Start Date04 May 2024

Sponsor / Collaborator

Iran University of Medical Sciences & Health Services

ChiCTR2400083577 / SuspendedPhase 4

A randomized, controlled clinical study of low-molecular-weight heparin improving pregnancy outcomes in recurrent implantation failure women undergoing frozen embryo transfer cycles

Start Date01 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Heparin Calcium

100 Translational Medicine associated with Heparin Calcium

100 Patents (Medical) associated with Heparin Calcium

62,156

Literatures (Medical) associated with Heparin Calcium

31 Dec 2024·Renal failure

Comparison of citrate dialysate in pre- and post-dilution online hemodiafiltration: effect on clot formation and adequacy of dialysis in hemodialysis patients

Article

Author: Homjan, Monpinya Charttong ; Laykhram, Thanachit ; Trakarnvanich, Thananda ; Jitraree, Arisara ; Nakornchai, Pasu

BACKGROUND:

Citrate dialysate (CD) has been successfully used in conventional hemodialysis and continuous renal replacement therapy; however, no study has compared pre- and post-dilution online hemodiafiltration (oL-HDF). Therefore, we aimed to investigate the efficacy of citrate anticoagulation for oL-HDF and the metabolic changes and quality of life of patients on hemodialysis treated using both modes.

METHOD:

Eight dialysis patients were treated with CD containing 0.8 mmol of citric acid for 4 weeks in each phase. Visual clotting scores were investigated as the primary endpoints. Adequacy of dialysis, laboratory parameters, and quality of life were measured as secondary objectives.

RESULTS:

The mean clotting scores in the pre-dilution mode were significantly lower than those in the post-dilution mode and in all phases except the heparin-free phase (p < 0.001 in the baseline phase, p = 0.001 in phase 1, and p = 0.023 in phase 2). The values of Kt/V in both modalities were comparable except during the baseline phase, in which the values of pre-dilution were significantly greater than post-dilution (2.36 ± 0.52/week vs. 1.87 ± 0.33/week;95% CI -0.81 to -0.19, p = 0.002). The patient's quality of life regarding their physical activity level was significantly higher in the post-dilution mode than in the pre-dilution mode at baseline and in phase 1 (p = 0.014 and 0.004 at baseline and in phase 1, respectively). Metabolic changes did not differ between the two modes.

CONCLUSION:

Citrate dialysate decreased or prevented anticoagulation in both pre- and post-dilution modes of oL-HDF without significant side effects and had comparable adequacy of dialysis.

30 Dec 2024·Acta neurologica Taiwanica

Cerebral Venous Thrombosis Presenting as Simultaneous Intracerebral Hemorrhage.

Article

Author: Aguilar-Fuentes, Victor ; Jiménez-Ruiz, Amado ; Ruiz-Sandoval, José Luis ; Benavides-Gómez, Fernando

A 37-year-old pregnant woman presented to the emergency department with central facial palsy, ipsilateral right hemiparesis, and seizures. Brain Computed Tomogram (CT) showed intracerebral hemorrhage (ICH) and bilateral frontal edema. Magnetic resonance imaging (MRI) revealed multifocal hemorrhages consistent with a diagnosis of multiple simultaneous ICH (MSICH) (Figure 1). We suspected cerebral venous thrombosis (CVT) and performed a MR angiogram confirming this diagnosis (Figure 2). Upon admission, the patient was treated with low-molecular-weight heparin and transitioned to direct oral anticoagulation at discharge. Non traumatic MSICH is a rare imaging finding with high mortality, usually arterial in origin (1). However, since treatment options vary, cerebral venous thrombosis should always be considered in the differential diagnosis, especially in young female patients with known risk factors, such as pregnancy and puerperium (2-4). MRI modalities (Echo-GRE) are valuable tools in identifying ICH when CT is inconclusive (5).

01 Dec 2024·Applied microbiology and biotechnology

Anionic extracellular polymeric substances extracted from seawater-adapted aerobic granular sludge

Article

Author: Pronk, Mario ; Chen, Le Min ; van Ede, Jitske ; van Loosdrecht, Mark C M ; Beck, Paula ; Lin, Yuemei

Anionic polymers, such as heparin, have been widely applied in the chemical and medical fields, particularly for binding proteins (e.g., fibroblast growth factor 2 (FGF-2) and histones). However, the current animal-based production of heparin brings great risks, including resource shortages and product contamination. Recently, anionic compounds, nonulosonic acids (NulOs), and sulfated glycoconjugates were discovered in the extracellular polymeric substances (EPS) of aerobic granular sludge (AGS). Given the prevalence of anionic polymers, in marine biofilms, it was hypothesized that the EPS from AGS grown under seawater condition could serve as a raw material for producing the alternatives to heparin. This study aimed to isolate and enrich the anionic fractions of EPS and evaluate their potential application in the chemical and medical fields. The AGS was grown in a lab-scale reactor fed with acetate, under the seawater condition (35 g/L sea salt). The EPS was extracted with an alkaline solution at 80 °C and fractionated by size exclusion chromatography. Its protein binding capacity was evaluated by native gel electrophoresis. It was found that the two highest molecular weight fractions (438- > 14,320 kDa) were enriched with NulO and sulfate-containing glycoconjugates. The enriched fractions can strongly bind the two histones involved in sepsis and a model protein used for purification by heparin-column. These findings demonstrated possibilities for the application of the extracted EPS and open up a novel strategy for resource recovery. KEY POINTS: • High MW EPS from seawater-adapted AGS are dominant with sulfated groups and NulOs • Fifty-eight percent of the EPS is high MW of 68-14,320 kDa • EPS and its fractions can bind histones and fibroblast growth factor 2.

127

News (Medical) associated with Heparin Calcium

18 Jun 2024

·www.globenewswire.com

CorMedix Inc. Receives FDA Feedback on Potential Label Expansion

BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback to the Company’s request to discuss development plans for additional indications for DefenCath. The FDA provided supportive feedback regarding the Company’s plans to pursue an expanded indication in adult Total Parenteral Nutrition (TPN) patients. CorMedix expects to submit a complete clinical protocol to FDA in the 3rd quarter with a goal of gaining further alignment and initiating the program by the end of 2024. In addition, the FDA confirmed its requirement that the Company conduct a study in pediatric hemodialysis (HD) patients under the Pediatric Research Equity Act (PREA). CorMedix intends to pursue the development of DefenCath for the expanded indication of the prevention of Central Line Associated Blood Stream Infections (CLABSI) in adult patients receiving TPN through a central venous catheter. The Company recently engaged an independent third party to conduct a TPN market assessment, and based on their analysis, believes there is a critical unmet medical need for DefenCath in this patient population. The data estimates the rate of CLABSI in TPN patients to be greater than 25%, and that the total addressable market for DefenCath in TPN is driven by approximately 5 million infusions per year. Patients receiving TPN that contract a CLABSI experience materially higher rates of hospital admission and readmission, as well as significant increases in patient mortality. CorMedix intends to share additional data related to the TPN market opportunity on the Company’s second quarter earnings call in August. Joseph Todisco, CorMedix CEO, commented, “I am pleased with FDA’s feedback and am excited about the opportunity to advance a development program for this highly vulnerable patient population. Given the high rate of CLABSI in patients receiving TPN, we have seen significant inbound interest for study participation by clinical investigators. Provided we obtain FDA’s concurrence on the final study protocol in a timely manner, we hope to commence a TPN program before the end of 2024.” DefenCath® (taurolidine and heparin)IMPORTANT SAFETY INFORMATION These highlights do not include all the information needed to use DefenCath safely and effectively. See full prescribing information for DefenCath. LIMITED POPULATION: DefenCath is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. DefenCath is contraindicated and has warnings and precautions in patients with: Known heparin-induced thrombocytopenia (HIT).Known hypersensitivity to any drug products in DefenCath, including taurolidine, heparin or the citrate excipient or pork products. If exposure to either of the above occurs, discontinue use of DefenCath and institute appropriate supportive measures. To report any safety concerns including suspected adverse reactions, contact CorMedix Inc. at 1-888-424-6345 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. Please see the full Prescribing Information. About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023 and launched in inpatient settings in April 2024. CorMedix anticipates the commercial launch of DefenCath in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisors(617) 430-7576

Drug Approval

17 Jun 2024

·www.prnewswire.com

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ -- Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe. Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions. In Europe, MTPC first received approval for Argatroban in Sweden in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, the UK, France, Spain and Italy. Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II. Denis Delval, CEO of Ethypharm, said: "We are delighted to strengthen our portfolio of essential drugs and bring Argatroban to patients in Europe. Furthermore, we are proud to take over this product following its originator, the well-recognized Mitsubishi Tanabe Pharma Corporation." About Ethypharm Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine. Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment. Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations. The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms. With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets. Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them. To find out more about Ethypharm, visit About Mitsubishi In Europe, MTPC's subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as "MTPD, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners. Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group remains committed to delivering pharmaceutical products to patients in Europe through MTPE and MTPD, including the continued supply of Radicava® (edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, thereby making a meaningful contribution to those facing diseases in the region. The company's six production sites are located in France, the UK, Spain and China. About Mitsubishi Tanabe Pharma Group Mitsubishi Tanabe Pharma Corporation (MTPC), a member of the Mitsubishi Chemical Group, is committed to delivering pharmaceutical products to patients in Europe through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). This includes the continued supply of Radicava® (edaravone), the treatment agent for amyotrophic lateral sclerosis, thereby making a meaningful contribution to those facing diseases in the region. In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of argatroban in the UK and Germany, among other European countries, through their respective networks of partners. Logo - Media contact: Ethypharm: Avril Ponnelle, [email protected]

Drug ApprovalAcquisition

06 Jun 2024

·www.globenewswire.com

CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years. While vascular access for hemodialysis can be initiated in an inpatient setting, ambulatory surgical centers or vascular access centers offer a less-invasive, outpatient-based alternative for patients. The company estimates that up to 100,000 HD-CVC placements occur each year, and pass-through status ensures that providers are reimbursed separately for administration of DefenCath in this setting of care. Given that approximately 50% of catheter-related bloodstream infections, or CRBSIs, can occur within the first 90 days that a catheter is inserted, it is critical to protect the line beginning at the time of placement. DefenCath® (taurolidine and heparin)IMPORTANT SAFETY INFORMATION These highlights do not include all the information needed to use DefenCath safely and effectively. See full prescribing information for DefenCath. LIMITED POPULATION: DefenCath is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. DefenCath is contraindicated and has warnings and precautions in patients with: Known heparin-induced thrombocytopenia (HIT).Known hypersensitivity to any drug products in DefenCath, including taurolidine, heparin or the citrate excipient or pork products. If exposure to either of the above occurs, discontinue use of DefenCath and institute appropriate supportive measures. To report any safety concerns including suspected adverse reactions, contact CorMedix Inc. at 1-888-424-6345 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. Please see the full Prescribing Information. About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023 and launched in inpatient settings in April 2024. CorMedix anticipates the commercial launch of DefenCath in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisors(617) 430-7576

100 Deals associated with Heparin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D04427	Heparin Calcium	S01XA14 B01AB01 C05BA03	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	GB	Ockham Biotech Ltd.	30 Jan 2022
Cystic Fibrosis	Phase 1	GB	Ockham Biotech Ltd.	30 Jan 2022
Asthma	Preclinical	GB	Ockham Biotech Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	Colorectal Cancer	614	Extended duration thromboprophylaxis with low-molecular-weight-heparin	rajajqsdvn(wlxauoscxd) = ojprvaptum vqhoakboei (dtkupjdacq ) View more	-	10 Dec 2023
				Standard duration thromboprophylaxis	rajajqsdvn(wlxauoscxd) = ayatnflycj vqhoakboei (dtkupjdacq ) View more
ESC2023	Not Applicable	-	768	Heparin dose 50IU/kg	catgyddztk(iruumtlbhk) = nrvusuwqni lwxvigelsr (bstepikvvq )	-	27 Aug 2023
				Heparin dose ≥70IU/kg	catgyddztk(iruumtlbhk) = yccekrbtzu lwxvigelsr (bstepikvvq )
NCT03894904 (CTgov)	Phase 4	Anesthesia \| Vasospasm	100	Heparin+Papaverine (Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed)	uqkgqxfrly(fnsdqlmrxt) = egunebeaab mhcmqemebc (dzauhlvswt, aywrhjogtx - izgydxvaki) View more	-	27 Oct 2022
				Heparin+Rescue papaverine, as needed (Heparin During Procedure, With Rescue Papaverine as Needed)	uqkgqxfrly(fnsdqlmrxt) = zkwzsivzlw mhcmqemebc (dzauhlvswt, amwjnzulwm - tgcahzkgnb) View more
Highlow Study (ISTH2022)	Not Applicable	Venous Thromboembolism D-dimer \| PAP \| von Willebrand factor (vWF) ... View more	217	Intermediate-dose low-molecular-weight heparin	gkdtnwsjly(xdthvpyyvp) = ecqkbkifli apebsqsgzv (chfteaetwz )	-	09 Jul 2022
				Low-dose low-molecular-weight heparin	gkdtnwsjly(xdthvpyyvp) = nhagknczxb apebsqsgzv (chfteaetwz )
Pubmed \| Cancer Nurs	Not Applicable	Acute Lymphoblastic Leukemia	61	Heparin (Normal saline)	rmlknkqadd(sfoddqyzmg) = Adverse events did not differ between groups rhkkptxycj (zmotkwtgds )	-	05 Feb 2022
ESC2021	Not Applicable	COVID-19 respiratory infection	3,458	Standard prophylactic heparin doses	kuqhnipkwh(ixadcgbgll): RR = 1.06 (95% CI, 0.58 - 1.95) View more	-	27 Aug 2021
				Higher heparin doses
ISTH2021	Not Applicable	Complications of bariatric procedures	-	Weight-adjusted LMWH regimens	dcbmnmjigp(adhggqwtmh) = cqpwgdldlg gzrbrdudlk (jnvxprfgxl ) View more	-	17 Jul 2021
				Non-weight adjusted LMWH regimens	dcbmnmjigp(adhggqwtmh) = dilheueibt gzrbrdudlk (jnvxprfgxl ) View more
ERA2021	Not Applicable	Infection of hemodialysis catheter	-	Sodium Heparin Lock Solution	mudwptwdix(zhdaonbpge) = slightly lower on Bic-lock phase ihkacxbvvg (jypevdheia ) View more	-	29 May 2021
				Sodium Bicarbonate Lock Solution
MO871 (ERA2021)	Not Applicable	Heparin-induced thrombocytopenia anti-heparin antibody \| antiheparin-PF4 ELISA test \| platelet aggregation test with heparin	64	Hemodialysis with unfractionated heparin	laezoikkuu(ehwvgcxpku) = bbynypohns guwmrqypqn (tekbiwuyvr ) View more	Positive	29 May 2021
				Heparin	dhnaavyigm(stxwnvlyjv) = dsiulipnrl ccczaykmqb (ufvcacrgcm ) View more
EVOCIT (Pubmed \| Am J Kidney Dis)	Not Applicable	-	26	Evocit (heparin-grafted dialyzer combined with a 1.0 mmol/L citrate-enriched dialysate)	kpcjcgwfjb(vyemsujkmd) = prxzbxdkcq rxqhrldeav (rpixqydgiq )	Positive	30 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Heparin Calcium

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation